Interestingly, the combined blockade of TNFR1, TRAIL-R and CD95 seems to give excellent results in the prevention of inflammation caused by the respective ligands, whereas targeting these receptors individually did not have that effect (WO2019141862) as demonstrated in a murine model of dermatitis [320]. The gene discussed is TNFRSF1A; the disease is skin disorder.